Trending at Lumira Ventures

Edesa Biotech Receives C$14 million from the Government of Canada to complete the clinical study of its investigational drug EB05, for the treatment of hospitalized COVID-19 patients.

Abi Kumar Edesa Biotech, Portfolio News

TORONTO, ON / ACCESSWIRE / February 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to complete the Phase 2 portion of …